Comparative Pharmacology
Head-to-head clinical analysis: MYCHEL versus MYCHEL S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYCHEL versus MYCHEL S.
MYCHEL vs MYCHEL-S
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mychel is a topical antifungal agent that inhibits ergosterol synthesis by binding to fungal cytochrome P450 14α-demethylase, disrupting fungal cell membrane integrity.
Sulconazole inhibits fungal cytochrome P450 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Adults: 200 mg orally twice daily for 14 days.
200 mg orally every 12 hours for 14 days
None Documented
None Documented
Terminal half-life: 8.5-12 hours (mean 10.2 h) in normal renal function; prolonged to 18-30 h in severe renal impairment (CrCl <30 mL/min)
3-4 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
Renal: ~70% unchanged; fecal: ~15% as metabolites; biliary: ~10%
Renal: 70-80% as unchanged drug via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Category C
Category C
Antibiotic
Antibiotic